Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13
TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis, announced today that it will host a conference call and webcast on Wednesday, March 13, 2018, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter and year ended December 31, 2018.
Conference Call & Webcast:
Wednesday, March 13th @ 8:30am Eastern Time.
Within the US: 877-425-9470
Outside the US: 201-389-0878
From Israel: 1 809 406 247
Conference ID: 13687890
Webcast: http://public.viavid.com/index.php?id=133389
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations. Galmed recently announced top-line results of the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase 2b clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing for an end of Phase 2b meeting with the FDA to discuss the results of the ARREST Study and a Phase 3/4 study protocol, with a view to initiating a Phase 3/4 clinical study of Aramchol in 2019.
SOURCE Galmed Pharmaceuticals Ltd.
Share this article